CO-55: Service denied as experimental or investigational

The payer is telling you that, under the member's benefit plan and their medical policy, the billed service is classified as experimental or investigational. In their view there is not enough accepted evidence yet for safety, effectiveness, or standard use for this diagnosis or setting, so they will not cover it as a benefit. Mechanically, the denial fires when your CPT, HCPCS, or revenue code hits a payer policy flagged as experimental for that diagnosis, age, or place of service, or when the plan excludes that therapy category in general. The unpaid amount is marked as contractual (CO), which means you must write it off unless you successfully appeal and get the service reclassified as covered or paid under an exception.

Behavioral health sees CO-55 on newer or nonstandard therapies that have not been adopted into payer policies yet. Examples are certain TMS protocols for non‑MDD diagnoses, ketamine infusions for depression or PTSD, virtual reality exposure therapies, and new digital CBT platforms billed under unlisted codes. Even when a psychiatrist or psychologist documents strong clinical rationale, payers often still follow a standing policy that calls the service experimental. At the level‑of‑care level, PHP or IOP programs that build in emerging treatments can trigger CO-55 when billed as separate codes on top of the per‑diem, especially with commercial plans and some MCOs. Carve‑out behavioral health plans may also flag add‑on services in MAT and OTP settings, such as off‑label medications or device therapies, as investigational even if the core OTP per‑diem is paid. Telehealth can be hit when you use tele‑codes for services that the payer's policy only recognizes in‑person, so a group therapy or family code done by video might be labeled investigational for that plan and place of service.

• Confirm the exact CPT or HCPCS code, modifiers, revenue code, and diagnosis on the denied line and compare to the payer EOB remark codes.
• Pull the specific payer medical policy and benefit booklet for that member to see how the service is defined and if it is listed as experimental or excluded.
• Check the chart to confirm the clinical indication, prior treatments tried, and any prior authorization or case management notes that might support a medical exception.
• If policy allows exceptions, write a focused appeal with supporting literature, treatment guidelines, and a strong provider letter of medical necessity, and submit as an appeal, not a corrected claim.
• If the policy clearly excludes the service as a benefit, adjust the balance as contractual and update your fee schedule or program design to stop future unbillable cases.
• If the denial conflicts with a written prior authorization or pre‑service approval, include that proof and request a reconsideration citing the authorization reference and dates.

• During verification of benefits, ask specifically whether the planned service or technology is covered for that diagnosis and place of service, and document any exclusions.
• Load payer-specific rules into your scrubber or cheat sheets that flag codes and therapies that are on payer experimental lists so staff can discuss cash‑pay or alternatives up front.
• Standardize medical necessity letters and consent forms for emerging treatments so providers document failed standard therapies, guidelines, and supporting evidence from day one.
• Review denial trends with clinical leadership each quarter and adjust program offerings, coding choices, or payer contracting when a therapy is routinely written off as experimental.